HOX Therapeutics
Pre-clinicalHOX is a preclinical-stage biotechnology company focused on the discovery and development of novel, targeted medicines for the treatment of prostate cancer.
Founded
2019
Focus
Small Molecules
About
HOX is a preclinical-stage biotechnology company focused on the discovery and development of novel, targeted medicines for the treatment of prostate cancer.
Funding History
1Total raised: $2.5M
Seed$2.5MUndisclosedJun 15, 2022
Company Info
TypePrivate
Founded2019
LocationLondon, United Kingdom
StagePre-clinical
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile